Guardant Health, Inc. (NASDAQ:GH) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Guardant Health, Inc. (NASDAQ:GH) have received an average rating of “Moderate Buy” from the twenty-four ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation and twenty-three have given a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $96.7143.

A number of equities analysts have commented on GH shares. JPMorgan Chase & Co. upped their price objective on shares of Guardant Health from $90.00 to $120.00 and gave the stock an “overweight” rating in a research report on Monday, December 15th. Guggenheim increased their price target on shares of Guardant Health from $56.00 to $67.00 and gave the stock a “buy” rating in a report on Thursday, September 25th. Leerink Partners raised their price objective on shares of Guardant Health from $115.00 to $155.00 and gave the company an “outperform” rating in a research report on Monday, December 15th. Wolfe Research upgraded Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 target price on the stock in a research report on Thursday, September 25th. Finally, Cowen reissued a “buy” rating on shares of Guardant Health in a report on Thursday, October 30th.

Insider Buying and Selling

In other news, CEO Helmy Eltoukhy sold 90,565 shares of the stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $103.82, for a total value of $9,402,458.30. Following the completion of the transaction, the chief executive officer owned 2,047,143 shares in the company, valued at $212,534,386.26. This trade represents a 4.24% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Ian T. Clark sold 28,611 shares of the firm’s stock in a transaction dated Friday, December 5th. The shares were sold at an average price of $107.19, for a total transaction of $3,066,813.09. Following the completion of the sale, the director owned 9,851 shares of the company’s stock, valued at $1,055,928.69. This trade represents a 74.39% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 426,663 shares of company stock valued at $44,508,069 in the last quarter. Corporate insiders own 6.10% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in GH. Signaturefd LLC lifted its position in shares of Guardant Health by 50.5% during the 2nd quarter. Signaturefd LLC now owns 635 shares of the company’s stock valued at $33,000 after acquiring an additional 213 shares during the period. IFP Advisors Inc increased its stake in Guardant Health by 120.1% in the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company’s stock valued at $33,000 after purchasing an additional 334 shares in the last quarter. Allworth Financial LP raised its holdings in Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company’s stock worth $37,000 after purchasing an additional 552 shares during the last quarter. Sound Income Strategies LLC acquired a new position in Guardant Health during the third quarter worth $38,000. Finally, Optiver Holding B.V. boosted its position in Guardant Health by 153.5% during the third quarter. Optiver Holding B.V. now owns 768 shares of the company’s stock worth $48,000 after purchasing an additional 465 shares in the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

Guardant Health Stock Up 0.1%

NASDAQ GH opened at $102.59 on Friday. The firm has a market cap of $12.93 billion, a P/E ratio of -31.96 and a beta of 1.58. Guardant Health has a 52-week low of $29.91 and a 52-week high of $112.43. The business’s 50-day moving average price is $95.28 and its 200 day moving average price is $68.92.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.09. The business’s revenue for the quarter was up 38.5% on a year-over-year basis. During the same period last year, the firm earned ($0.88) EPS. As a group, analysts anticipate that Guardant Health will post -2.9 earnings per share for the current year.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.